文献速递膀胱癌与上尿路尿路上皮癌

序贯膀胱内化疗治疗初治高危非肌层浸润性膀胱癌:肿瘤学结局、耐受性及与同期对照的比较

Sequential Intravesical Chemotherapy for Treatment Naïve, High-Risk Non-Muscle Invasive Bladder Cancer: Oncologic Outcomes, Tolerance, and Comparison to Contemporary Controls.
PubMed 文献 · Urology · 2024-06-19

单中心回顾性队列研究纳入80例初治高危非肌层浸润性膀胱癌患者,其中53例接受吉西他滨-多西他赛序贯膀胱内化疗,27例接受卡介苗。两组12个月和24个月无复发生存率无显著差异,吉西他滨-多西他赛组不良事件发生率显著更低(40% vs 74%)。作者认为序贯膀胱内吉西他滨-多西他赛是有效且可能耐受性更好的卡介苗替代方案。

要点

  • 吉西他滨-多西他赛组12个月无复发生存率87%、24个月75%,卡介苗组分别为85%和81%,无显著差异。
  • 吉西他滨-多西他赛组不良事件发生率40%,显著低于卡介苗组的74%。
  • 作者认为序贯膀胱内吉西他滨-多西他赛是初治高危非肌层浸润性膀胱癌有效且可能耐受性更好的卡介苗替代方案。

核心结论

  • 作者认为序贯膀胱内吉西他滨-多西他赛是初治高危非肌层浸润性膀胱癌有效且可能耐受性更好的卡介苗替代方案。

研究设计与样本

  • 单中心回顾性队列研究,纳入2020年8月至2023年8月间开始一线吉西他滨-多西他赛或卡介苗治疗的80例初治高危非肌层浸润性膀胱癌患者。
  • 随访采用膀胱镜检查、尿细胞学检查和横断面影像学检查。
  • 主要肿瘤学结局为监测期间高级别膀胱肿瘤复发,采用Kaplan-Meier法确定治疗开始后12个月和24个月无复发生存率。
  • 评估每种膀胱内治疗的耐受性。

主要发现

  • 80例中53例(66%)接受吉西他滨-多西他赛,27例(34%)接受卡介苗,总体中位随访18个月。
  • 吉西他滨-多西他赛组复发10例,卡介苗组复发7例。
  • 吉西他滨-多西他赛组12个月无复发生存率87%、24个月75%,卡介苗组分别为85%和81%,无显著差异。
  • 吉西他滨-多西他赛组不良事件发生率40%,显著低于卡介苗组的74%。

临床怎么用

  • 作者认为序贯膀胱内吉西他滨-多西他赛是初治高危非肌层浸润性膀胱癌有效且可能耐受性更好的卡介苗替代方案。

局限性

  • 回顾性设计。
  • 队列样本量小。
  • 肿瘤学随访时间中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess if receiving sequential intravesical chemotherapy (Gemcitabine-Docetaxel, Gem-Doce) therapy was associated with similar oncologic efficacy to bacillus Calmette-Guérin (BCG) in patients with treatment-naïve, high-risk non-muscle invasive bladder cancer (HR-NMIBC). METHODS: Single-center, retrospective cohort study of 80 patients with HR-NMIBC initiating first-line Gem-Doce or BCG between August 2020 and August 2023. Surveillance was conducted with cystoscopy, urine cytology, and cross-sectional imaging. The primary oncologic outcome was high-grade bladder tumor recurrence during surveillance. Kaplan-Meier method was applied to determine 12- and 24-month recurrence-free survival (RFS) after initiation of therapy. Tolerance of each intravesical therapies was assessed. RESULTS: About 53/80 (66%) received Gem-Doce and 27/80 (34%) received BCG with overall 18-month median follow-up. There were 10 recurrences after Gem-Doce and 7 after BCG. The RFS at 12- and 24-months for Gem-Doce (12-months: 87%, 24-months: 75%) was not significantly different than BCG (12-months: 85%, 24-months: 81%). Lastly, Gem-Doce had significantly fewer patients with AEs compared to BCG (40% vs 74%). Limitations include retrospective design, small cohort size, and intermediate oncologic follow-up. CONCLUSION: Our data suggest that sequential intravesical Gem-Doce is an oncologically efficacious and, potentially better tolerated, alternative to BCG for treatment-naïve HR-NMIBC.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Refugia JM, Roebuck E, Thakker P, et al. Sequential Intravesical Chemotherapy for Treatment Naïve, High-Risk Non-Muscle Invasive Bladder Cancer: Oncologic Outcomes, Tolerance, and Comparison to Contemporary Controls. Urology. 2024. PMID: 38906268. doi:10.1016/j.urology.2024.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。